Yesterday, the CVP, Critical Care & Vascular of Edwards Lifesciences (NYSE: EW), Catherine Szyman, sold shares of EW for $1.37M.
This is Szyman’s first transaction since reporting a Sell transaction on MDT back in August 2013 In addition to Catherine Szyman, one other EW executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Edwards Lifesciences’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $895 million and quarterly net profit of $207 million. In comparison, last year the company earned revenue of $884 million and had a net profit of $230 million. EW’s market cap is $29.3B and the company has a P/E ratio of 52.91. Currently, Edwards Lifesciences has an average volume of 1.43M.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $156.50, reflecting a -12.1% downside. Five different firms, including Citigroup and J.P. Morgan, currently also have a Sell rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
